Anti-IL6 high affinity antibody, Mouse monoclonal

clone IL6-2A3, purified from hybridoma cell culture

Anti-CTL differentiation factor (CDF), Anti-Hybridoma growth factor, Anti-B-cell stimulatory factor 2 (BSF-2), Anti-Interferon beta-2 (IFN-beta-2), Anti-Interleukin-6
Pricing and availability is not currently available.

Quality Level

biological source


antibody product type

primary antibodies


IL6-2A3, monoclonal


buffered aqueous solution

species reactivity



~1.0 mg/mL


ELISA: suitable
immunoblotting: 0.125-0.25 μg/mL using recombinant human IL6 expressed in HEK-293T cells
immunoprecipitation (IP): 10-20 μg/test using concentrated supernatant of human osteosarcoma MG-63 cells treated with IL1β



UniProt accession no.

shipped in

dry ice

storage temp.


Gene Information

human ... IL6(3569)

General description

Interleukin-6 (IL6) is a multifunctional cytokine.


recombinant human IL6


Anti-IL6 high affinity antibody, Mouse monoclonal has been used in
  • immunoblotting
  • immunoprecipitation

Biochem/physiol Actions

Interleukin-6 (IL6) plays a wide variety of important biological roles in the immune, nervous and endocrine system. It is an essential component for hybridoma growth and is found in many supplemental cloning media. IL6 regulates acute and chronic inflammatory diseases and has been proven to be an excellent target for clinical treatment against autoimmune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis and Castleman′s disease. IL6 also plays a key role in the pathogenesis of multiple myeloma.

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.


NONH for all modes of transport

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificate of Analysis
Certificate of Origin
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma
Voorhees PM, et al.
British Journal of Haematology, 161(3), 357-366 (2013)
IL-6 in autoimmune disease and chronic inflammatory proliferative disease
Ishihara K and Hirano T
Cytokine & Growth Factor Reviews, 13(4-5), 357-368 (2002)
Luca Semerano et al.
Expert opinion on investigational drugs, 23(7), 979-999 (2014-04-29)
IL-6 is a key cytokine in the pathogenesis of rheumatoid arthritis (RA). The clinical efficacy of tocilizumab (TCZ), a humanized anti-IL6-receptor mAb, confirmed the value of IL-6 blockade in this disease. A number of new anti-IL-6 biologics are currently in...
P M Ridker et al.
The New England journal of medicine, 336(14), 973-979 (1997-04-03)
Inflammation may be important in the pathogenesis of atherothrombosis. We studied whether inflammation increases the risk of a first thrombotic event and whether treatment with aspirin decreases the risk. We measured plasma C-reactive protein, a marker for systemic inflammation, in...
Mehmet Kocoglu et al.
Pharmaceuticals (Basel, Switzerland), 9(1) (2016-01-20)
Multiple myeloma is the second most common hematologic malignancy. The treatment of this disease has changed considerably over the last two decades with the introduction to the clinical practice of novel agents such as proteasome inhibitors and immunomodulatory drugs. Basic...

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.